CompletedNot Applicable

Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.

Switzerland20 participantsStarted 2021-09-16

Plain-language summary

In this pilot study the feasibility continous recording of vital signs in pediatric patients under chemotherapy for cancer, is studied. Vital signs and are recorded with two different wearable devices (WDs): Everion®, by Biovotion (now Biofourmis), Zurich, Switzerland and CORE® by GreenTEG, Zurich, Switzerland. Patients can choose if they want to wear one or both WDs during this study. Those opting to wear two WDs can choose if they want to wear them in parallel, or sequentially. Results from the two different WDs will be compared. Study duration for each participant is 14 days per device.

Who can participate

Age range1 Month – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chemotherapy treatment because of any malignancy, expected to last ≥1 month at time of recruitment for myelosuppressive therapy; or at least one cycle of myeloablative therapy requiring autologous (Bern/Basel) or allogeneic (Basel) hematopoietic stem cell transplantation. * Age from 1 month to 17.99 years at time of recruitment * Written informed consent from parents and participants, where applicable Exclusion Criteria: * Local skin diseases prohibiting wearing of the WD. * Denied written informed consent from participants

What they're measuring

Feasibility of continous recording of core temperature with the two wearable devices (WDs)

Timeframe: 14 days

Trial details

NCT IDNCT04914702

SponsorInsel Gruppe AG, University Hospital Bern

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-03-01

View on ClinicalTrials.gov More Pediatric Cancer trials